Contribute Try STAT+ Today

In a bid to contain prescription drug prices, a pair of U.S. senators is re-introducing a bill to have the Government Accountability Office probe the role of pharmacy benefit managers in the opaque pharmaceutical supply chain.

The legislation is only the latest effort to focus on these controversial middlemen, which create formularies, or lists of medicines that are covered by insurance. In the process, pharmacy benefit managers collect rebates from drug makers, a controversial tactic because the deals are blamed for rising drug prices, but the amounts are kept confidential.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.